Hiseco announced that its subsidiary Shanghai Hiseco Pharmaceutical Technology Co., Ltd. recently received the "Acceptance Notice" from the National Medical Products Administration, involving two new indications for the innovative drug HSK 44,500 tablets: psoriasis and atopic dermatitis. At present, HSK 44,500 tablets has obtained clinical trial notifications for "interstitial lung disease" and "Behcet's disease" and is undergoing Phase I clinical research. HSK 44,500 tablets is a small molecule drug independently developed by the company, with independent intellectual property rights, clear targets, definite efficacy, good safety, and broad prospects for clinical application.